Cargando…

Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation

In 10% of ischemic strokes, non-valvular atrial fibrillation (NVAF) is detected retroactively. Milder, or even asymptomatic forms of NVAF have shown high mortality, thrombotic risk, and deterioration of cognitive function. The current guidelines for the diagnosis and treatment of AF contain “grey ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachieru, Ciprian, Luca, Constantin-Tudor, Văcărescu, Cristina, Petrescu, Lucian, Cirin, Liviu, Cozma, Dragos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590594/
https://www.ncbi.nlm.nih.gov/pubmed/37873054
http://dx.doi.org/10.2147/CIA.S427748
_version_ 1785124022186409984
author Rachieru, Ciprian
Luca, Constantin-Tudor
Văcărescu, Cristina
Petrescu, Lucian
Cirin, Liviu
Cozma, Dragos
author_facet Rachieru, Ciprian
Luca, Constantin-Tudor
Văcărescu, Cristina
Petrescu, Lucian
Cirin, Liviu
Cozma, Dragos
author_sort Rachieru, Ciprian
collection PubMed
description In 10% of ischemic strokes, non-valvular atrial fibrillation (NVAF) is detected retroactively. Milder, or even asymptomatic forms of NVAF have shown high mortality, thrombotic risk, and deterioration of cognitive function. The current guidelines for the diagnosis and treatment of AF contain “grey areas”, such as the one related to anticoagulant treatment in men with CHA2DS2-VASc score 1 and women with score 2. Moreover, parameters such as renal function, patient weight or left atrium remodelling are missing from the recommended guidelines scores. Vulnerable categories of patients including the elderly population, high hemorrhagic risk patients or patients with newly diagnosed paroxysmal episodes of atrial high rate at device interrogation are at risk of underestimation of the thrombotic risk. This review presents a systematic exposure of the most important gaps in evaluation of thrombotic and hemorrhagic risk in patients with NVAF. The authors propose new algorithms and risk factors that should be taken into consideration for an accurate thrombotic and hemorrhagic risk estimation, especially in vulnerable categories of patients.
format Online
Article
Text
id pubmed-10590594
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105905942023-10-23 Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation Rachieru, Ciprian Luca, Constantin-Tudor Văcărescu, Cristina Petrescu, Lucian Cirin, Liviu Cozma, Dragos Clin Interv Aging Review In 10% of ischemic strokes, non-valvular atrial fibrillation (NVAF) is detected retroactively. Milder, or even asymptomatic forms of NVAF have shown high mortality, thrombotic risk, and deterioration of cognitive function. The current guidelines for the diagnosis and treatment of AF contain “grey areas”, such as the one related to anticoagulant treatment in men with CHA2DS2-VASc score 1 and women with score 2. Moreover, parameters such as renal function, patient weight or left atrium remodelling are missing from the recommended guidelines scores. Vulnerable categories of patients including the elderly population, high hemorrhagic risk patients or patients with newly diagnosed paroxysmal episodes of atrial high rate at device interrogation are at risk of underestimation of the thrombotic risk. This review presents a systematic exposure of the most important gaps in evaluation of thrombotic and hemorrhagic risk in patients with NVAF. The authors propose new algorithms and risk factors that should be taken into consideration for an accurate thrombotic and hemorrhagic risk estimation, especially in vulnerable categories of patients. Dove 2023-10-18 /pmc/articles/PMC10590594/ /pubmed/37873054 http://dx.doi.org/10.2147/CIA.S427748 Text en © 2023 Rachieru et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Rachieru, Ciprian
Luca, Constantin-Tudor
Văcărescu, Cristina
Petrescu, Lucian
Cirin, Liviu
Cozma, Dragos
Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title_full Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title_fullStr Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title_full_unstemmed Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title_short Future Perspectives to Improve CHA(2)DS(2)VASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation
title_sort future perspectives to improve cha(2)ds(2)vasc score: the role of left atrium remodelling, inflammation and genetics in anticoagulation of atrial fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590594/
https://www.ncbi.nlm.nih.gov/pubmed/37873054
http://dx.doi.org/10.2147/CIA.S427748
work_keys_str_mv AT rachieruciprian futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation
AT lucaconstantintudor futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation
AT vacarescucristina futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation
AT petresculucian futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation
AT cirinliviu futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation
AT cozmadragos futureperspectivestoimprovecha2ds2vascscoretheroleofleftatriumremodellinginflammationandgeneticsinanticoagulationofatrialfibrillation